Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 13, 2016 7:12 PM ET


Company Overview of AstraZeneca Pharmaceuticals LP

Company Overview

AstraZeneca Pharmaceuticals LP, a biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription medicines to customers worldwide. It offers medicines primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases. The company was founded in 1912 and is headquartered in Wilmington, Delaware. It has research and development, manufacturing, and commercial office locations in California, Delaware, Kentucky, Massachusetts, Maryland, North Carolina, Ohio, and Pennsylvania. AstraZeneca Pharmaceuticals LP operates as a subsidiary of AstraZeneca PLC.

1800 Concord Pike

PO Box 15437

Wilmington, DE 19850-5437

United States

Founded in 1912





Key Executives for AstraZeneca Pharmaceuticals LP

Chief Financial Officer and Vice President of Finance - North America
Executive Vice President of North America and President of Astrazeneca US
President of Astrazeneca Canada Inc
Vice President of Medical Affairs and US Head Medical Officer
Chief Operating Officer of U.S. Business
Age: 55
Compensation as of Fiscal Year 2015.

AstraZeneca Pharmaceuticals LP Key Developments

Cerulean Pharma Inc. Enters into Lease Agreement with Astrazeneca Pharmaceuticals Limited Partnership

On July 9, 2015, Cerulean Pharma Inc. (the Company) entered into a lease agreement (the Lease) with AstraZeneca Pharmaceuticals Limited Partnership, a Delaware limited partnership (the Landlord), for approximately 22,992 square feet of laboratory and office space at 35 Gatehouse Drive in Waltham, Massachusetts. The term of the Lease commences on December 28, 2015 and expires on February 28, 2021. During each of the first two years of the term, the Company's annual base rent will be $689,760. The annual base rent shall increase each year thereafter. In addition to the base rent, the Company is also responsible for its share of the operating expenses, utility costs and real estate taxes, in accordance with the terms of the Lease. Pursuant to the terms of the Lease, the Company is required to provide a security deposit in the form of a letter of credit in the amount of $229,920. The Company has the right to extend the term of the Lease for one three-year term, provided that the Company provides notice to the Landlord not later than 12 months prior to the expiration date of the initial term. The base rent for the extension term, if any, will be determined based on market conditions existing at such time in accordance with the terms of the Lease. The Lease contains customary provisions allowing the Landlord to terminate the Lease if the Company fails to remedy a default of any of its obligations under the Lease within specified periods or upon the bankruptcy or insolvency of the Company.

Faruqi & Faruqi, LLP and Berger & Montague,P.C. Reach Whistleblower Lawsuit Settlement with AstraZeneca Pharmaceuticals LP, Cephalon, Inc., and Biogen Inc

Faruqi & Faruqi, LLP and co-counsel Berger & Montague,P.C. announced that they have reached a settlement in three separate but related whistleblower lawsuits alleging violations of the False Claims Act against AstraZeneca Pharmaceuticals LP, Cephalon, Inc., and Biogen Inc., for a total of $55.5 million. The cases were jointly prosecuted by Faruqi & Faruqi, LLP and Berger & Montague, P.C. on behalf of Relator Ronald J. Streck, who filed this action in 2008. Under the terms of the settlement, AstraZeneca will pay $46.5 million, Cephalon will pay $7.5 million, and Biogen will pay $1.5 million. Claims against a fourth drug manufacturer, Genzyme Corporation, are still being litigated. The case, pending in federal court in the Eastern District of Pennsylvania, is captioned United States ex rel. Ronald Streck versus Allergan, et al., Case No. 08-cv-5135. The lawsuit, filed on behalf of the United States under the False Claims Act (FCA) and State False Claims Acts alleges that a number of pharmaceutical manufacturers, including AstraZeneca, Cephalon and Biogen, fraudulently underpaid mandatory rebates to state Medicaid programs. Streck's lead attorney, T. Talyana Bromberg of Faruqi & Faruqi, LLP, stated: "When pharmaceutical companies manipulate prices in order to underpay Medicaid, every taxpayer suffers.

The Third U.S. Circuit Court of Appeals Affirms Dismissal of a Relator's False Claims Act Suit Against Bristol-Meyers Squib Co., E.I. du Pont de Nemours and Co., DuPont Pharmaceuticals Co., AstraZeneca Pharmaceuticals L.P. and AstraZeneca L.P

The Third U.S. Circuit Court of Appeals affirmed the dismissal of a relator's False Claims Act (FCA) suit against pharmaceutical companies, agreeing with a district court that the relator failed to show he was the original source of information about the companies' alleged wrongdoing. Karl Schumann, proceeding as a qui tam relator under the FCA and corresponding state laws, brought an action against Bristol-Meyers Squib Co., E.I. du Pont de Nemours and Co., DuPont Pharmaceuticals Co., AstraZeneca Pharmaceuticals L.P. and AstraZeneca L.P. (collectively, the defendants). Schumann alleged the defendants improperly induced Medco Health Solutions Inc., his employer, to offer certain of the defendants' drugs in its mail-order pharmacies and in health plans it managed; did not include those inducements when calculating the best price for their drugs and thus submitted inaccurate best price reports to the government; overcharged the government based on those inaccurate best prices; and underpaid rebates owed based on those inaccurate best prices. The district court found it lacked subject matter jurisdiction over Schumann's claims because he did not have the requisite direct and independent knowledge to satisfy the original source exception to the FCA's public disclosure bar. As a result, the court dismissed Schumann's claims with prejudice. Schumann appealed. The Third Circuit affirmed the district court's judgment. In so ruling, the Third Circuit found Schumann's knowledge gained through the application of expertise to information publicly disclosed under 31 U.S.C. §3730(e)(4)(A) was not independent, and Schumann failed to aver facts indicating he had direct and independent knowledge of any false or fraudulent claim submitted or caused to be submitted by the defendants. Therefore, Schumann was not an original source of the information underlying his FCA claims against the defendants.

Similar Private Companies By Industry

Company Name Region
CR, LLC United States
Legacy Pharmaceuticals US, Inc. United States
Clinical Supplies Management, Inc. United States
acelerate, Inc. United States
Technical Resources International, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact AstraZeneca Pharmaceuticals LP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at